The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
HOME > ACADEMIA
ACADEMIA
- Impact of Oligonucleotides - 3: Advances in Modified Oligo Technologies Pave Way for Innovative Drug Arrivals
January 20, 2020
- Nagasaki Univ., Kobe Foundation Tie Up on Clinical Development
January 17, 2020
- Impact of Oligonucleotides - 2: Expert Says Spinraza Changed SMA Treatment Paradigm, Has High Expectation for Zolgensma Too
January 17, 2020
- Impact of Oligonucleotides - 1: Onpattro a Major Advance in FAP Treatment, but Challenges Remain
January 16, 2020
- Leading IBD Care Hospital Switches to Infliximab Biosimilars; Will Others Follow Suit?
January 7, 2020
- 5-Year Cancer Survival Rate Rises 0.3 Point to 66.4%: NCC
December 17, 2019
- 8,000 Die from 2 Drug Resistant Bacteria Annually in Japan: Survey
December 9, 2019
- Low-Dose Aspirin Might Cut Dementia Risks in Diabetes Women: Researchers
December 5, 2019
- National Neurology Center Starts Investigator-Led Trial for DMD Drug Targeting Exon 44
November 8, 2019
- Academic Society Calls for Caution in Using Xofluza in Patients Under Age 12
October 28, 2019
- Nephrology Society Poised to Compile Drug Development Guidelines for Early-Stage Kidney Disease
October 18, 2019
- Cancer Institute Hospital Opens Development Center to Resolve Challenges of Immunotherapy with Pharma Companies
October 18, 2019
- Research Group at Tokyo Medical and Dental Univ. Succeeds in Producing Multi-Organ Structure from iPS Cells
September 27, 2019
- Drug Makers Evaluating MSLs Using Both Qualitative, Quantitative Criteria: JAPhMed Survey
September 25, 2019
- High Response Rate in Brain Metastasis Patients Earned High Marks for Rozlytrek’s Sakigake Status: Oncologist
September 6, 2019
- Anticoagulant Monotherapy Does Not Increase CV Events in Coronary Artery Disease Patients with AF: Cardiovascular Center
September 6, 2019
- 4 Scientific Societies Submit Proposal to Health Minister to Ensure Stable Antibiotic Supplies
September 4, 2019
- Investigator-Led Clinical Trial to Get Underway for Next-Gen Oncolytic Virus
August 28, 2019
- 80% of Diabetes Patients on Antihypertensives Use ACE Inhibitors/ARBs: MHLW Study
August 19, 2019
- 5-Year Cancer Survival Rates in Japan Stand at 66.1%: NCC
August 9, 2019
ページ
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Japan’s pharmaceutical industry has been in dire need of a shake-up, and as we continue to grapple with the COVID-19 pandemic, one thing is remarkably clear. It’s no longer business as usual, and we’re enjoying a front-row seat to some…